2 The technology
2.2 The most common adverse reactions (in more than 20% of patients) were: anaemia, fatigue, diarrhoea, thrombocytopenia, nausea, pyrexia, dyspnoea, respiratory tract infection, cough and peripheral oedema. For full details of adverse reactions and contraindications, see the summary of product characteristics. 
2.4 The list price of carfilzomib is £1,056 for a 60-mg vial (excluding VAT; Monthly Index of Monthly Specialties online, accessed October 2016). 
From cycle 1 to 12: £5,127 (no wastage), £6,336 (wastage).
From cycle 13: £3,418 (no wastage), £4,220 (wastage). 
£10,644 (no wastage), £12,627 (wastage).
The company has a commercial arrangement. This makes carfilzomib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.